Business
Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID
Long COVID Impacts Up To 30% of COVID-19 Patients Activation of Dormant Herpes Virus Infections are Hypothesized as a Potential Trigger of Long COVID
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":"\n\nLong COVID Impacts Up To 30% of COVID-19 Patients\n\n\nActivation of Dormant Herpes Virus Infections are Hypothesized as a Potential Trigger of Long COVID\n\n\nCombination Therapy with IMC-2 (valacyclovir and celecoxib) Expands Virios’ Pipeline\n\n\n ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today a collaboration with the Bateman Horne Center (“BHC”) of Salt Lake City, Utah, to explore the role of combination antiviral therapy in Long COVID, otherwise known as Post-Acute Sequelae of COVID-19 . The Bateman Horne Center is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), fibromyalgia (“FM”), post-viral syndromes, and related comorbidities.\n\nVirios Therapeutics, Inc. is providing BHC with an unrestricted grant for an investigator-sponsored study to explore the therapeutic potential of combination antiviral therapy with Virios’ second development candidate, IMC-2. The study will evaluate changes in common Long COVID symptoms such as fatigue, sleep, attention, pain, autonomic function and anxiety.\n\n“We are pleased to support the Bateman Horne Center, a leading clinical research center in post-viral syndromes, as they study the therapeutic potential of IMC-2 to ease the burden of Long COVID, which is an emerging healthcare crisis,” said Greg Duncan, Chairman and CEO of Virios Therapeutics Inc.\n\nAccording to the World Health Organization, COVID-19 has caused more than 373 million infections and more than 5.6 million deaths as of January 2022. Published estimates in the scientific literature suggest that up to 30% will experience Long COVID symptoms. It is estimated that one in three patients who develop Long COVID symptoms were asymptomatic during their acute COVID-19 infection. The mechanisms by which COVID-19 causes lingering symptoms are not well understood. Potential triggers for long term symptoms might include:\n\n\nImmune-system dysregulation triggered by the COVID-19 virus, including increased production of autoantibodies,\n\n\nLingering or re-infection with COVID-19 variants, and\n\n\nCo-infection or activation of previous viral infecti...